Developing targeted therapies for kidney diseases using nanoparticles
Official title: Nanoparticle-targeted therapeutic development for glomerular diseases
Funded at City College of New York · NIH-11002161 · Data updated 2026-11-12
This study is working on new treatments for kidney diseases, especially for those that can lead to serious kidney problems, and it's aimed at helping people, particularly in African American communities, by using tiny particles to deliver medicine right to the kidneys.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | City College of New York NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 23, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $266,087 |
| NIH project number | 1U54MD017979-01A1 |
| Project ID | NIH-11002161 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals suffering from chronic kidney disease or those at risk of progressing to end-stage kidney disease, particularly within the African American community.
✕Less likely to help
Patients with kidney diseases not related to glomerular conditions or those who do not belong to the targeted demographic may not benefit from this research.
What this research studies
This research focuses on creating innovative therapies specifically designed to target kidney diseases, particularly glomerular diseases that can lead to end-stage kidney disease (ESKD). The project involves a collaborative team of experts in biomedical engineering, cell biology, nephrology, and pharmacology, who aim to translate laboratory findings into clinical applications. By utilizing biocompatible nanoparticles, the research seeks to improve the delivery of treatments directly to the affected kidney cells, potentially reducing the burden of chronic kidney disease and its complications. The study also addresses health disparities, particularly among African American populations who are disproportionately affected by these conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for kidney diseases, improving patient outcomes and reducing the need for dialysis or transplants.
How similar studies have gone: Previous research has shown promise in using targeted nanoparticle therapies for various diseases, indicating potential success for this novel approach in kidney disease treatment.
Where this research is happening
-
City College of New York
New York, United States Active
Researchers
- Principal investigator: Williams, Ryan Martin — City College of New York
- Study coordinator: Williams, Ryan Martin
Related research
Other NIH-funded projects on the same topics.
-
Nonpeptide drugs to boost nerve growth for spinal cord repair
A study in animals explores small molecule drugs that can cross into the brain and help nerve fibers regrow after spinal cord injury, with the goal of restoring some function.
-
Onsite PTSD Treatment to Improve MOUD Outcomes for people who inject drugs
A community-based program will adapt a PTSD therapy and deliver it alongside opioid-use treatments to help people who inject drugs stay engaged in care and improve outcomes.
-
Understanding how neuron numbers and wiring patterns are set in the brain
A scientist at a major university is studying how sensory neurons determine how many there should be and how large their branches are, using fruit fly brain cells to learn about brain development and potentially human brain injuries.
-
Community Outreach and Education Core to Advance Cancer Prevention and Equity
A community-based program in New York partners CCNY and MSK to spread proven cancer prevention and early detection practices and to pave the way for precision prevention in diverse communities.
-
Cancer research education and mentorship program for students and early-career investigators
A program to mentor and give hands-on cancer research experience to undergraduate and graduate students and early-stage investigators.
-
Planning and Evaluation Core for Translational Cancer Research Partnership
A planning and evaluation program helps cancer care partners coordinate, monitor progress, and share findings to move new cancer research into real patient benefits.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.